Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00006849
DRKS00006849
Active, Not Recruiting
N/A

Therapeutic Response and Neurobiological Prediction Markers in Auditory Verbal Hallucinations

Translational Research Center, Division of Systems Neuroscience of Psychopathology, University Hospital of Psychiatry0 sites12 target enrollmentNovember 6, 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsF20F25F23SchizophreniaSchizoaffective disordersAcute and transient psychotic disorders

Overview

Phase
N/A
Intervention
Not specified
Conditions
F20
Sponsor
Translational Research Center, Division of Systems Neuroscience of Psychopathology, University Hospital of Psychiatry
Enrollment
12
Status
Active, Not Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 6, 2014
End Date
June 30, 2018
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Translational Research Center, Division of Systems Neuroscience of Psychopathology, University Hospital of Psychiatry

Eligibility Criteria

Inclusion Criteria

  • •ICD\-10: patients of the University Hospital of Psychiatry in Bern with schizophrenia (F20\), acute and transient psychotic disorder (F23\), or schizoaffective disorder (F25\), prone to AVH in the acute phases of the disorder
  • •Patients not declining conventional antipsychotic treatment (Treatment arms A, F, G) or patients declining conventional antipsychotic treatment (Treatment arm B\-E)
  • •Right\-handedness
  • •Able to give informed written consent to participate in the study and ability to follow the procedures of the study (no language problems, psychological disorders, dementia, etc.)

Exclusion Criteria

  • •Involuntary commitment (individuals with symptoms of severe mental illness endangering themselves or others are committed into treatment in a hospital)
  • •Other psychiatric or neurological disorder than F20 or F25
  • •Skin disease on the head
  • •Participation in other clinical studies
  • •Non\-removable metallic components (splinters, cardiac pacemakers, metal clips, metal implants, cochlear\-implants, insulin pumps, etc.)
  • •Tattoos on or near the head
  • •Permanent make\-up
  • •Claustrophobia
  • •Signs of increased cerebral excitability (EEG)
  • •For female patients:

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
The Neurobiological Foundations of Treatment Response in Children with Developmental Dyslexia: An exploratory studyeerstoornisDyslexiaReading Disorder
NL-OMON42443Radboud Universiteit Nijmegen41
Active, Not Recruiting
Phase 1
A study searching for the factors predicting ketamine´s antidepressant effect
EUCTR2018-001539-39-CZárodní ústav duševního zdraví40
Recruiting
N/A
Sequential neuromodulation (cathodal tDCS primed TMS and ECT) in treatment resistant depressioHealth Condition 1: F33- Major depressive disorder, recurrentHealth Condition 2: F32- Major depressive disorder, singleepisode
CTRI/2021/05/033784Department of Psychiatry National Institute of Mental Health and Neuro Sciences
Completed
N/A
Prediction of the therapeutic response and adverse events to methotrexate by monitoring methotrexate-polyglutamates (MTX-PGs) concentration in erythrocytes in Japanese patients with rheumatoid arthritis (RA).
JPRN-UMIN000020134Jichi Medical University56
Recruiting
N/A
Prediction of therapy response and treatment outcomes in early course of schizophrenia.Subproject D1_AP2 of the research network ESPRIT (Enhancing Schizophrenia Prevention and Recovery through Innovative Treatments)DSM IV-TR:295.10-30, 295.90: Schizophrenia High Risc State of transmission to psychosis
DRKS00010936Klinik und Poliklinik für Psychiatrie und Psychotherapie,LVR-Klinikum Düsseldorf / Kliniken der Heinrich Heine Universität Düsseldorf600